EUVIMEDEUVIMED entdecken
Crossref

The GPR40 novel agonist SZZ15 ‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice

Lei Lei iD, Xuefeng Gao, Jiayu Zhai, Shuainan Liu, Quan Liu, Caina Li, Hui Cao, Cunyu Feng, Leilei Chen, Liran Lei, Xuan Pan, Pingping Li und 3 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Lei Lei und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Homeostasis, Non-alcoholic Fatty Liver Disease, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Outstanding Young Scientist Program, Chinese Academy of Medical Sciences Initiative for Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Non‐alcoholic fatty liver is the most common cause of chronic liver disease. GPR40 is a potential therapeutic target for energy metabolic disorders. GPR40 is a potential therapeutic target for energy metabolic disorders. SZZ15‐11 is a newly synthesized GPR40 agonist. In this study, we estimate the potency of SZZ15‐11 in fatty liver treatment.

Methods

In vivo, diet‐induced obese (DIO) mice received SZZ15‐11 (50 mg/kg) and TAK875 (50 mg/kg) for 6 weeks. Blood glucose and lipid, hepatocyte lipid and liver morphology were analysed. In vitro, HepG2 cells and GPR40‐knockdown HepG2 cells induced with 0.3 mM oleic acid were treated with SZZ15‐11. Triglyceride and total cholesterol of cells were measured. At the same time, the AMPK pathway regulating triglycerides and cholesterol esters synthesis was investigated via western blot and quantitative polymerase chain reaction in both liver tissue and HepG2 cells.

Results

SZZ15‐11 was found to not only attenuate hyperglycaemia and hyperlipidaemia but also ameliorate fatty liver disease in DIO mice. At the same time, SZZ15‐11 decreased triglyceride and total cholesterol content in HepG2 cells. Whether examined in the liver of DIO mice or in HepG2 cells, SZZ15‐11 upregulated AMPKα phosphorylation and then downregulated the expression of the cholesterogenic key enzyme 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase and inhibited acetyl‐CoA carboxylase activity. Furthermore, SZZ15‐11 promotes AMPK activity via [cAMP] i accumulation.

Conclusion

This study confirmed that SZZ15‐11, a novel GPR40 agonist, improves hyperlipidaemia and fatty liver, partially via G s signalling and the AMPK pathway in hepatocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AMP-Activated Protein KinasesHomeostasisNon-alcoholic Fatty Liver DiseaseObesityReceptors, G-Protein-CoupledSignal TransductionAnimalsHumansMaleMiceDiet, High-FatHep G2 CellsHepatocytesLiverMice, Inbred C57BLMice, ObeseTriglycerides

Stichwörter der Autor:innen

3‐hydroxy‐3‐methylglutaryl coenzyme A reductaseAMPKGPR40 agonistacetyl‐CoA carboxylasehyperlipidaemianon‐alcoholic fatty liver

Substanzen

AMP-Activated Protein KinasesFfar1 protein, mouseReceptors, G-Protein-CoupledTriglycerides

Autor:innen und Institutionen

  • Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Key laboratory of Polymorphic Drugs of Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical…
  • Diabetes Research Center of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Lei Lei, Yi Huan, Zhufang Shen

Förderung

  • National Natural Science Foundation of China
  • Beijing Outstanding Young Scientist Program
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine

Zitieren

APA

Lei, L., Gao, X., Zhai, J., Liu, S., Liu, Q., Li, C., Cao, H., Feng, C., Chen, L., Lei, L., Pan, X., Li, P., Liu, Z., Huan, Y., & Shen, Z. (2024). The GPR40 novel agonist SZZ15 ‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15539

Vancouver

Lei L, Gao X, Zhai J, Liu S, Liu Q, Li C, et al. The GPR40 novel agonist SZZ15 ‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15539

BibTeX
@article{Lei2024,
  author = {Lei, Lei and Gao, Xuefeng and Zhai, Jiayu and Liu, Shuainan and Liu, Quan and Li, Caina and Cao, Hui and Feng, Cunyu and Chen, Leilei and Lei, Liran and Pan, Xuan and Li, Pingping and Liu, Zhanzhu and Huan, Yi and Shen, Zhufang},
  title = {The GPR40 novel agonist SZZ15 ‐11 improves non‐alcoholic fatty liver disease by activating the AMPK pathway and restores metabolic homeostasis in diet‐induced obese mice},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15539}
}
Kostenlos starten →